Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1975 1
1976 3
1977 2
1978 2
1979 2
1980 3
1981 4
1982 6
1983 8
1984 7
1985 5
1986 9
1987 15
1988 11
1989 12
1990 12
1991 14
1992 29
1993 26
1994 34
1995 26
1996 35
1997 37
1998 31
1999 38
2000 49
2001 43
2002 48
2003 52
2004 52
2005 59
2006 49
2007 71
2008 61
2009 70
2010 75
2011 106
2012 119
2013 146
2014 145
2015 155
2016 166
2017 154
2018 127
2019 135
2020 160
2021 196
2022 158
2023 161
2024 68

Text availability

Article attribute

Article type

Publication date

Search Results

2,504 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Resectable Oropharyngeal Squamous Cell Carcinoma"
Page 1
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M. Wise-Draper TM, et al. Clin Cancer Res. 2022 Apr 1;28(7):1345-1352. doi: 10.1158/1078-0432.CCR-21-3351. Clin Cancer Res. 2022. PMID: 35338369 Free PMC article. Clinical Trial.
PURPOSE: Patients with resected, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%-69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune-checkpoint …
PURPOSE: Patients with resected, local-regionally advanced, head and neck squamous cell carcinoma …
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665297 Free PMC article. Clinical Trial.
PURPOSE: Pembrolizumab improved survival in patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), …
PURPOSE: Pembrolizumab improved survival in patients with recurrent or metastatic head and neck squamous-cell …
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Ferris RL, et al. J Clin Oncol. 2022 Jan 10;40(2):138-149. doi: 10.1200/JCO.21.01752. Epub 2021 Oct 26. J Clin Oncol. 2022. PMID: 34699271 Free PMC article. Clinical Trial.
Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index. RESULTS: Credentialed surgeons performed TOS for 495 patients. ...Exploratory comparison of functional assessment of cancer therapy …
Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagi …
Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN).
Porceddu SV, Daniels C, Yom SS, Liu H, Waldron J, Gregoire V, Moore A, Veness M, Yao M, Johansen J, Mehanna H, Rischin D, Le QT. Porceddu SV, et al. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):641-651. doi: 10.1016/j.ijrobp.2020.03.024. Epub 2020 Apr 11. Int J Radiat Oncol Biol Phys. 2020. PMID: 32289475
Radiation therapy (RT) consensus contouring guidelines in the postoperative setting for complex cutaneous squamous cell carcinoma of the head and neck have been developed by expert clinicians in the field of head and neck and derma …
Radiation therapy (RT) consensus contouring guidelines in the postoperative setting for complex cutaneous squamous cell car …
Target delineation for postoperative treatment of head and neck cancer.
Evans M, Beasley M. Evans M, et al. Oral Oncol. 2018 Nov;86:288-295. doi: 10.1016/j.oraloncology.2018.08.011. Epub 2018 Oct 12. Oral Oncol. 2018. PMID: 30409314
Patients who undergo primary surgical resection for a Head and Neck Squamous Cell Carcinoma (HNSCC) are stratified post-operatively, based on the presence or absence of pathological risk factors for recurrence, to estimate their risk of t …
Patients who undergo primary surgical resection for a Head and Neck Squamous Cell Carcinoma (HNSCC …
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, Patel AA, Cheng AC, Watters AL, Bifulco C, Morris G, Rushforth L, Nemeth S, Urba WJ, Gough M, Bell RB. Leidner R, et al. J Immunother Cancer. 2021 May;9(5):e002485. doi: 10.1136/jitc-2021-002485. J Immunother Cancer. 2021. PMID: 33963014 Free PMC article. Clinical Trial.
BACKGROUND: Checkpoint inhibitors targeting programmed death receptor-1 (PD-1) have been tested in the neoadjuvant setting for the treatment of locoregionally advanced head and neck squamous cell carcinoma (HNSCC); however, response rates are mo …
BACKGROUND: Checkpoint inhibitors targeting programmed death receptor-1 (PD-1) have been tested in the neoadjuvant setting for the treatment …
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Ferris RL, et al. J Immunother Cancer. 2021 Jun;9(6):e002568. doi: 10.1136/jitc-2021-002568. J Immunother Cancer. 2021. PMID: 34083421 Free PMC article. Clinical Trial.
BACKGROUND: Head and neck squamous cell carcinomas (HNSCCs) are common malignancies caused by carcinogens, including tobacco and alcohol, or infection with human papillomavirus (HPV). Immune checkpoint inhibitors targeting the programmed cell de …
BACKGROUND: Head and neck squamous cell carcinomas (HNSCCs) are common malignancies caused by carcinogens, inclu …
Machine Learning-Guided Adjuvant Treatment of Head and Neck Cancer.
Howard FM, Kochanny S, Koshy M, Spiotto M, Pearson AT. Howard FM, et al. JAMA Netw Open. 2020 Nov 2;3(11):e2025881. doi: 10.1001/jamanetworkopen.2020.25881. JAMA Netw Open. 2020. PMID: 33211108 Free PMC article.
OBJECTIVE: To evaluate whether machine learning models could identify patients with intermediate-risk head and neck squamous cell carcinoma who would benefit from chemoradiation. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included pati …
OBJECTIVE: To evaluate whether machine learning models could identify patients with intermediate-risk head and neck squamou …
Oligometastasis in Head and Neck Squamous Cell Carcinoma.
Moon DH, Sher DJ. Moon DH, et al. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):803-811. doi: 10.1016/j.ijrobp.2022.06.086. Epub 2022 Jul 4. Int J Radiat Oncol Biol Phys. 2022. PMID: 35798219 Review.
Up to 40% of patients who present with, or later develop, metastatic disease from head and neck squamous cell carcinoma have oligometastatic disease, defined as 5 or fewer sites of metastasis. ...Although surgical resection has been the t …
Up to 40% of patients who present with, or later develop, metastatic disease from head and neck squamous cell …
Selected E2F2 Polymorphisms in Oral and Oropharyngeal Squamous Cell Carcinoma.
Gołąbek K, Biernacki K, Gaździcka J, Strzelczyk JK, Miśkiewicz-Orczyk K, Krakowczyk Ł, Zięba N, Kiczmer P, Ostrowska Z, Misiołek M. Gołąbek K, et al. Biomed Res Int. 2021 Mar 30;2021:8098130. doi: 10.1155/2021/8098130. eCollection 2021. Biomed Res Int. 2021. PMID: 33860054 Free PMC article.
Oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) are subgroups of head and neck squamous cell carcinoma. E2F Transcription Factor 2 (E2F2) could contribute to …
Oral squamous cell carcinoma (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) are s …
2,504 results